Diabetes Business Overview

Dedicated to Delivering the Best

Our insulin pumps and continuous glucose monitoring devices meet both paediatric needs and adult requirements.  We design our products so that both children and adults living with type 1 diabetes can enjoy life the way they want to.

Effectively controlling glucose levels (or gaining improved glycaemic control) can help patients with diabetes to reduce the long term health risks associated with diabetes and to improve their quality of life.

Insulin Pump Therapy

Today’s pumps are miniaturised and designed to the scale of “companion machines” such as MP3 players and mobile phones. Studies show that insulin pump therapy reduces hypoglycaemia and A1C levels compared to multiple daily injections.* The demand for insulin pumps continues to increase, reflecting the success of these devices in fulfilling the health needs of people with type 1 diabetes.

Insulin pump therapy is recommended by the National Institute for Health and Clinical Excellence (NICE);

for adults and children 12 years and older with type 1 diabetes mellitus provided that:

  • attempts to achieve target haemoglobin A1c (HbA1c) levels with multiple daily injections (MDIs) result in the person experiencing disabling hypoglycaemia. For the purpose of this guidance, disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life

or

  • HbA1c levels have remained high (that is, at 8.5% or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care.

CSII therapy is recommended as a treatment option for children younger than 12 years with type 1 diabetes mellitus provided that:

  • MDI therapy is considered to be impractical or inappropriate, and
  • children on insulin pumps would be expected to undergo a trial of MDI therapy between the ages of 12 and 18 years.

Continuous Glucose Monitoring

A continuous glucose monitoring system consists of a tiny sensor which is inserted under the skin to continuously measure glucose levels in the body and a monitor to record and display the glucose measurements every 5 minutes. The continuous glucose monitoring system can also warn of increasing or decreasing glucose levels and can be downloaded for a complete and accurate picture of glucose patterns over time.

Web and PC-based Software Solutions

Our software tools integrate insulin pump, continuous glucose monitoring and BG metre data.  The broad sets of data are transformed into meaningful treatment information that support healthcare providers in optimising the prescribed therapy and easy to use reports that can help people with diabetes better manage their condition. The advanced internet-enabled functionality allows for the synchronisation of data available to patients and providers and offers the possibility to monitor patients' data remotely.

Consumables

These include infusion sets and insulin reservoirs used in conjunction with insulin pumps. Medtronic infusion sets reflect more than 20 years of customer feedback - which is why they are so easy to use, convenient and comfortable to wear. Each infusion set model was designed with specific users in mind to best match individual body types and lifestyles.

Accessories

Our wide range of accessories enhances the design and handling of the pump, from novelty and replaceable “SKINS” (pump covers) to cases, clips and carriers. There are accessories to suit the tastes of both adults and children.

Real progress toward a cure for diabetes

In 1983 Medtronic Diabetes pioneered continuous insulin delivery. Our first insulin pump was introduced in an undertaking to find a "better way" for people with type 1 diabetes to receive insulin.

Since then our business has maintained its reputation for excellence in insulin pump therapy and continuous glucose monitoring through innovation and continual demonstration of efficacy and safety through clinical evidence.

For nearly 30 years we have been steadfastly and steadily working towards achieving a dream: an artificial pancreas as a cure for diabetes. We are dedicated to that goal.

Reference

 

Last updated: 22 Sep 2010

Section Navigation

Additional information

NYSE (MDT)

Europe